FT GLOBAL PHARMACEUTICAL AND BIOTECHNOLOGY CONFERENCE 2007 Delegate... · FT GLOBAL PHARMACEUTICAL...

F T G L O B A L C O N F E R E N C E S & E V E N T S

FT GLOBALPHARMACEUTICALAND BIOTECHNOLOGYCONFERENCE 2007Convergence, Collaboration, and Customers: Driving Innovation, Accelerating Growth

3 & 4 December 2007The Cumberland, London

www.ftpharmabiotech.com

In association with

Sponsors

1341 PharmaBio Delegate Booklet 28/11/07 14:41

General information

DRINKS RECEPTION

A drinks reception will take place in the Ocean suite foyer from 17:00 on 3 December 2007.

FEEDBACK FORMS

These will be distributed towards the end of the first day of the event. We would very much appreciate your completedform being handed to the registration desk on departure from the conference.

MOBILE PHONES

As a courtesy to other delegates, please ensure your mobile phone is switched off while in the Conference room.

SECURITY

For security reasons it is important that you wear your conference badge at all times.

INTERNET ACCESS

Internet pods are located in the coffee break area for delegates to access. Should you wish to have wireless internet foryour laptop then please purchase an access code from the hotel info point in the coffee break area.

FIRE PROCEDURE

All delegates need to be aware of the procedures to be followed in the event of fire or if the fire alarm is sounded.Please familiarise yourself with the nearest emergency exits. If you discover a fire, immediately operate the nearestbreak glass call point, and notify a member of the conference or hotel staff. On hearing the alarm you shouldproceed immediately to the assembly point located on the hotel forecourt.

SPEAKER PRESENTATIONS AND AUDIO DOWNLOADS

These will be available to download from the FT Conferences website from Monday 17 December.

The access details are: www.ftconferences.com/pharmabiotechUsername/email address: [email protected]: papers

Please note that only presentations and audio downloads for which we have permission to publish will be available andthat these are subject to FT copyright rules. These can be viewed at www.ft.com


–– 3 ––

Welcome

Dear Guest

It is our great pleasure to welcome you to the FT Global Pharmaceutical and Biotechnology Conference here atthe Cumberland Hotel in London.

As the leading annual event in the industry calendar, the conference will provide you with the opportunity to gaincritical insights into the foremost trends and issues shaping your industry, and through the many participatorypanels and roundtables, will provide an unrivalled opportunity to network and share experience with your peers.

The theme of this year’s conference is “Convergence, Collaboration and Customers”. In an era when increasedcompetition and globalisation are the new realities of business, pharmaceutical and biotechnology companies areless likely to achieve future growth organically, and networking and collaborations of all kinds – through licensing andacquisitions, and through collaborations within and across the life sciences, medical devices and healthcare industryare set to become ubiquitous.

The big questions we will be asking each of our speakers are:

• How will the undying trends of convergence, collaboration and customer orientation change the landscape of thelife sciences and healthcare industries?

• How is value creation shifting across the industry value chain, and how can the opportunities for innovation beoptimised?

We hope that you will enjoy what promises to be an excellent event and that you will join us for the drinks receptionthis evening.

Yours,

Jayne Van HoenDirector, Global Conferences & EventsFinancial Times


–– 4 ––

Monday 3 December 2007

08:00 Registration and Coffee

09:00 CHAIR’S OPENING REMARKSMr Andrew Jack, Pharmaceutical Correspondent, Financial Times

New Avenues for Innovation in the GlobalPharmaceutical and Biotechnology Industries

Convergence: Driving Innovation, Accelerating Growth

• How will convergence transform the structure of the global lifesciences and healthcare industries? How is value creation shiftingacross all areas of the life sciences and healthcare value chain?

• How can opportunities for innovation through convergence beoptimised?

• Pharma and biotech: converging or diverging futures?

Mr Robert Wessman, President and CEO, Actavis GroupDr Lisa Drakeman, President and CEO, GenmabMr Angus Russell, Chief Financial Officer, Shire plc

Questions and Answers

10:00 Convergence in Practice: Devices, Drugs and IT

• Winners and losers in convergence: how can biotech, device anddiagnostic companies ensure that they are equal partners in theconvergence game?

• Implications for industry structure: to what extent will convergencelead to the evolution of pharma and biotech companies as broader‘healthcare companies’?

• Making convergence work: overcoming practical barriers to cross-sector convergence (e.g. managing expectations regarding timelinesfor R&D)

Dr Steven Powell, Chief Executive Officer, Plethora Solutions LimitedMr Simon Hammett, UK Life Sciences and Health Care Practice Leader,Deloitte


10:30 Leveraging Emerging Markets for Innovation andRevenue Growth

Mr Bob Go, Global Managing Director, Life Sciences and Health Care,Deloitte


10:45 Coffee

11:15 Waking to the Century of Networked Pharma

The Strategic Imperative of Collaboration, Partnershipsand Consolidation

• The implications of the networked pharma model? How isnetworking changing the fundamentals of the industry?

• Key to successful partnerships: overcoming organisational andcultural challenges

Dr Louise Makin, Chief Executive Officer, BTG plcMr Dan Zabrowski, Global Head Pharma Partnering, Roche


11:45 Public-Private Partnerships

• How can currently fragmented public and private R&D efforts bebrought together more efficiently to create truly life saving innovation?

• What is the opportunity for pharmaceutical and biotechnologycompanies in PPPs e.g. creating commercial spin-offs forpharmaceutical and biotechnology, and providing new funding,licencing and marketing opportunities for the biotech companies?

• How do PPPs work, and what is the key to their success? How canthe scope and effectiveness be improved?

Dr Jean-Pierre Paccaud, Director of Business Development,Drugs for Neglected Diseases initiative (DNDi)Dr Lynn Marks, Senior Vice President, Infectious Diseases MedicineDevelopment Centre, GlaxoSmithKline


12:15 Panel: Delivering Innovation through Effective Licensing– Next Frontiers

• Examining the opportunities and pitfalls of licensing in Asia andemerging markets: does licensing in emerging markets hold the keyto success of stand-alone biotech?

• Strategies for growth: licensing vs. M&A• Emerging licensing structures and deal terms-what are the

emerging innovations?

Dr Geoffrey Guy, Executive Chairman, GW Pharmaceuticals PlcDr Simon Moroney, Chief Executive Officer, MorphoSys AGMr John Mayo CBE, Managing General Partner, Celtic Pharma

12:45 Panel: Mergers and Acquisitions – Reshaping the Pharma Future?

• How will the current round of M&A transform the landscape of theindustry?

• What are the broader implications of pharma’s current appetite forbiotech acquisitions for innovation in the industry?

• What are the particular challenges relating to integrating biotechacquisitions for pharmaceutical companies? e.g. keeping the cultureof innovation alive?

• Assessing the implications of the rise of acquisitive emerging marketpharma companies as international players

Mr Shinichi Tamura, President and CEO, Sosei Group CorporationMr John Goddard, Senior Vice President, Strategic Planning andBusiness Development, AstraZeneca plcMs Kate Bingham, Managing Partner, SV Life Sciences

13:15 Networking Lunch

14:30 CHAIRMr Martyn Postle, Director and Founder,Cambridge Healthcare and Biotech Ltd

Leveraging Customer Collaboration

14:40 New Approaches to Collaboration with Government

Mr Meindert Boysen, Associate Director – Single TechnologyAppraisals, National Institute of Clinical Excellence (NICE)

15:00 Patients: Riding the Rising Tide of HealthcareConsumerism

Mr Simon Denegri, Chief Executive,Association of Medical Research Charities (AMRC)


15:30 Coffee

16:00 Innovation and the Global Pharmaceutical,Biotech and Medical Devices Industries

Exploring the Vital Link Between Pricing and Innovation:New Business Pricing Models and Reimbursement

Dr Panos Kanavos, Lecturer, International Health Policy,London School of EconomicsMs Ann Pope, Director, Markets and Projects-Goods,Office of Fair Trading (OFT)


16:30 Funding for Innovation

Dr Andy Richards, Early Stage Biotechnology InvestorMr Ted Bianco, Director of Technology Transfer, Wellcome Trust


17:00 Networking Drinks Reception

The organisers reserve the right to alter the programme and speakers as may be necessary.© Financial Times Limited 2007.


–– 5 ––

Tuesday 4 December 2007

08:30 Registration and Coffee

09:00 CHAIR’S OPENING REMARKSMs Salamander Davoudi, Biotechnology Correspondent, Financial Times

09:05 Keynote AddressMr Christian Siebert, DG Enterprise and Industry, European Commission


09:40 Revisiting the Fundamentals of Innovation

• Change as an innovation catalyst• Organisational and cultural challenges in innovation: governance and people strategy• Encouraging radical innovation to occur and be accepted• Innovation in life sciences: transforming R&D

Mr Rajiv Narang, Founder and CEO, Erehwon Innovation Consulting PvT LtdDr Emilio Emini, Executive Vice President, Vaccines Research and Development, Wyeth Pharmaceuticals


10:30 Innovation Strategies: is Big Pharma too Big and Biotech too Small to Innovate?Mr Luciano Conde, Chief Executive Operating Officer, Almirall


10:45 Driving Innovation: Transforming Patient Safety with AuthenticationMr Gary Noon, CEO, Aegate


11:00 Networking Coffee Break

11:30 Roundtable SessionsThe Impact of the Emerging Biopharma Model on the Supply Chain Hosted by

• The world of biologics: higher variability, lower yield, lower predictability• Examining supply chain implications of the migration from blockbuster drugs to targeted pharma solutions• New models in demand forecasting• New supply chain models: design for flexibility and selective outsourcing

Mr Reynold W (Pete) Mooney, Global Leader, Life Sciences Consulting, Deloitte Consulting LLP

Innovation Strategies: Creating an Environment that can Deliver Innovation Hosted by

• The importance of focusing on a franchise to drive growth• The relevance and importance of early collaboration with other departments• The importance of human capital: focus and skill• Securing and developing effective partnership agreements• Extending the product life cycle vs development of blockbuster therapies

Mr Luciano Conde, Chief Executive Operating Officer, Almirall

Healthcare Innovation: a Look at the Current and Future Role of Authentication in Patient Safety Hosted by

• Examining best practice examples across the globe • Explore where an authentication service currently used in the healthcare industry might fit in the future, i.e. hospitals, specialist

clinics or doctor surgeries • The opportunities authentication technology offers the market, particularly in terms of improved communication channels • Examine further opportunities for authentication in the pharmaceutical industry

Mr Brian Thornley, COO, Aegate

Aiming for Global Launch Excellence: Where to Focus for Success? Hosted by

• Engage all decision makers and expand markets • Adapt locally to new models • Align organisation, bridge silos • Optimise and adjust within the six month launch window

Mr John D MacCarthy, Vice President, Client Thought Leadership, IMS Health®

12:45 Networking Lunch

13:30 Roundtables (continued)

14:30 Pharma-Bio FuturesIn this concluding session of the conference, the panel will share their views on the major trends and future challenges facing the industry, and the likely impactof convergence, collaboration and customers on the industry’s innovation and growth strategies.

Mr Nick Lowcock, Managing Director, Warburg PincusMr Ton Gardeniers, Global Head of Healthcare, ABN Amro

15:00 Close of conference


–– 6 ––

Mr Ted BiancoDirector of Technology TransferWellcome Trust

Ted Bianco is Director of Technology Transfer at the Wellcome Trust withresponsibility for the promotion of early stage R&D through translationalresearch funding and the management of intellectual property arising fromWellcome Trust-sponsored research. Ted has 25 years experience in biomedicalresearch, specialising in tropical medicine and infectious disease. He obtainedhis PhD at the London School of Hygiene and Tropical Medicine andsubsequently worked at the Walter and Eliza Hall Institute in Melbourne, ImperialCollege of Science, Technology and Medicine in London and the Liverpool Schoolof Tropical Medicine, where he was the Walter Myers Professor of Parasitology.He joined the Wellcome Trust in 1999 as head of the Centres and Major Initiativesdepartment. Mr Bianco is an honourary professor of the Liverpool School.

Ms Kate BinghamManaging PartnerSV Life Sciences

Kate Bingham joined SV Life Sciences in 1991 and currently serves or hasserved on the boards of Affibody, Dynogen, Hexagen, Ingenium, LeukoSite,MedNova, Metris, Nexan, PowderMed, and Trine Pharmaceuticals. She hasalso been responsible for investments in Alantos, Auxilium, ESBATech,Genosis, Gyros, Kinetix, KuDOS, Lorantis and Micromet. Prior to joining SVLS,Ms Bingham worked in business development for Vertex Pharmaceuticals, abiotechnology company in Cambridge, MA and at Monitor Company, astrategy consulting firm. She has a masters degree in Biochemistry fromOxford University and graduated from Harvard Business School with an MBA.

Mr Luciano CondeChief Executive Operating OfficerAlmirall

Luciano Conde is Chief Operating Officer at Almirall. He is also Deputy Chairmanof the Management Board, Member of the Board of Directors, Co-chairman ofthe Pipeline Committee and President of the Operating Committee. Mr Condejoined Almirall in 1996 as Senior Commercial Director. He was promoted to hiscurrent position in 2002. Mr Conde has worked extensively in thepharmaceutical industry since 1981. Prior to joining Almirall, his most recentposition was with Pharmacia where, between 1993 and 1995, he was ExecutiveVice President, Director Open Care Manager, Site manager for MadridManufacturing and Commercial location, and a Member of the ManagementExecutive Committee. He has also previously worked at Farmitalia AntibióticosFarma, Roche Products (Pharma Division), Roche Products (Diagnostics) inSpain and Insalud (the Spanish national institute for health).

Mr Conde has a Pharmacy degree from the University Complutense (Madrid).He has also undertaken postgraduate studies in product marketing and sales,management, pharmaceutical marketing, and strategy for successful mergersand acquisitions.

Ms Salamander DavoudiBiotechnology CorrespondentFinancial Times

Salamander Davoudi joined the Financial Times as a journalist in 2003. She hasworked as a reporter covering the UK and European equity markets. In 2004she moved to the Washington bureau where she was responsible for coveringUS defence policy at the Pentagon. On her return to London she joined the UKcompanies team specialising in the support services sector. She has been thebiotechnology correspondent since 2006. She graduated from EdinburghUniversity and completed her Masters at Georgetown University in the US.

Mr Simon DenegriChief ExecutiveAssociation of Medical Research Charities

Simon Denegri joined AMRC as its Chief Executive in February 2006.Previously, Mr Denegri had been Director of Corporate Communications at theRoyal College of Physicians of London from 2003. He was Assistant ChiefExecutive at the Alzheimer’s Society (UK) from 2002 to 2003 and its Head ofPublic Affairs from 1992 until 1997. In the intervening period he was Corporateand Financial PR Manager at Procter & Gamble in the United States and thenDirector of Communications at the Sainsbury Centre for Mental Health(SCMH). He has written and spoken extensively on issues concerning healthand healthcare policy and practice.

Dr Lisa DrakemanPresident and Chief Executive OfficerGenmab

Dr Drakeman has served as Genmab’s President and Chief Executive Officersince the company’s inception. Dr Drakeman has over eighteen years ofexperience working in the biotechnology industry, including establishingcorporate partnerships with major pharmaceutical companies, managingclinical trials of monoclonal antibody-based products and developinggovernment programs for financing biotechnology research. In her position asChief Executive Officer, she has also set a number of financing records,including the largest private investment ever for a biotech company, the largestIPO ever by a European biotech company and the largest licensing transactionworldwide. Under Dr Drakeman’s leadership, Genmab received the James DWatson Helix Award as the best international biotechnology company in 2004for leadership in scientific innovation, company growth and corporatecitizenship. She has received a number of awards and honours including beingnamed “Advocate of the Year” by the Biotechnology Industry Organisation in1995, “Industry Woman of the Year” by the Biotechnology Council of New Jerseyin 1996, being inducted in the New Jersey High Technology Hall of Fame in2000 and one of “New Jersey’s Best 50 Women in Business" by NJBIZ in 2007.Dr Drakeman serves on board of the Biotechnology Council of New Jersey. Shepreviously served as a member of the faculty and administration at PrincetonUniversity and as Senior Vice President, Head of Business Development forMedarex, Inc. She received a B.A. degree, from Mount Holyoke College, M.A.,from Rutgers University, and M.A. and PhD, from Princeton University.

Speakers


–– 7 ––

Dr Emilio EminiExecutive Vice President, Vaccines Research and Development, Wyeth Pharmaceuticals

Dr Emilio Emini, is the executive vice president for Vaccine Research andDevelopment at Wyeth Pharmaceuticals, a position he has held since 2005.He leads an organisation of approximately 600 scientists and professionalsresponsible for research and development for Wyeth vaccines.

Prior to joining Wyeth, Dr Emini was the senior vice president for vaccinedevelopment at the International AIDS Vaccine Initiative (IAVI). He developedhis vaccine expertise from 1983 to 2004 at the Merck Research Laboratories,serving in eight positions. Dr Emini began his Merck tenure as a senior researchmicrobiologist, later assuming the directorship of HIV biology and immunology,serving as the executive director of the Department of Antiviral Research andthen becoming the senior vice president of vaccine and biologics research.

Since 2004, Dr Emini has chaired the National Institutes of Health (NIH) VaccineDevelopment Resources Committee and has served as a member if the NIHAIDS Vaccine Research Working Group. He is a fellow of the American Academyof Microbiology and a member of seven scientific societies, including the NewYork Academy of Sciences, the American Association for the Advancement ofScience, Sigma Xi and International Society for Antiviral Research.

He is a lecturer at three universities, educating students on medicalmicrobiology, graduate virology, viral pathogenesis at Hahnemann University,on graduate virology at the University of Pennsylvania, and on undergraduatevirology at Princeton University.

Mr Ton GardeniersGlobal Head of HealthcareABN Amro

Ton Gardeniers is the Global Head of Healthcare at ABN AMRO for the group’sglobal investment banking and corporate banking business and its varioussub-sectors. He joined ABN AMRO in 2000 and prior to that he was a SeniorInvestment Director with Gilde Investment Management in the Netherlands,responsible for the establishment of several biotech related venture capitalfunds. He was also Head of Corporate Finance for Rabobank North Americabased out of New York. Ton spent 14 years at JP Morgan Europe and New York,where he was involved in a variety of business lines including CorporateFinance and Capital Markets.

Mr Bob GoGlobal Managing Director, Life Sciencesand Health Care, Deloitte

Bob Go is Deloitte’s Global Leader for Industries and the Global ManagingDirector for Life Sciences and Health Care. In his nearly 30 years with Deloitte,Mr Go has worked with Boards of Directors and senior management of severalhundred companies on issues of corporate strategy, governance, Organisation,and business transformation.

In addition to his work with clients, he has also served as a member of theDeloitte & Touche USA LLP Board of Directors, including a period as its ViceChairman, and the Deloitte Consulting Management Committee. Mr Gocurrently participates as a guest member of the Board of Deloitte & ToucheCanada. Bob has spoken at Deloitte and external forums, includingpresentations at the World Economic Forum on issues concerning LifeSciences, innovation and future scenarios for China and India. He has an MBAfrom the University of Santa Clara.

Mr John GoddardSenior Vice President, Strategic Planning and Business Development, AstraZeneca plc

John Goddard was appointed Senior Vice President and Head of StrategicPlanning and Business Development for AstraZeneca in May 2006 and isbased in London. In addition, Mr Goddard is Chairman of Aptium HealthcareInc, a wholly owned subsidiary based in Los Angeles, which manages theprovision of outpatient cancer care and Chairman of AstraTech another whollyowned subsidiary, which develops, manufactures and markets advancedhealthcare devices for single use and dental implants.

Prior to moving to London, Mr Goddard was Senior Vice President and ChiefFinancial Officer for AstraZeneca in the United States and was responsible forall AstraZeneca Group finance matters in North America.

He began his career with Bell and Howell Limited, Rank Xerox and Spicer andPegler in the UK. He joined ICI in 1985 and worked in London until 1988, whenhe was appointed finance director for ICI Japan, based in Tokyo. In 1991, hebecame chief financial officer for ICI Asia Pacific based in Singapore, and wasappointed finance director for Zeneca Pharmaceuticals in 1993 back in the UK,a position he held through 1998 when he moved to the US.


–– 8 ––

Dr Geoffrey GuyExecutive ChairmanGW Pharmaceuticals Plc

Dr Guy has over twenty years experience in pharmaceutical developmentcovering new chemical entities, biotechnology products, plant-basedmedicines, controlled drugs and drug delivery systems. Dr Guy has been thephysician in charge of over 200 clinical studies including first dose in man,pharmacokinetics, pharmacodynamics, dose-ranging, controlled clinical trialsand large scale multi-centred studies and clinical surveys.

In 1981 Dr Guy moved into the pharmaceutical sector and joined Pierre FabreLaboratories in Castres, France where he subsequently became UK ClinicalTrials Co-ordinator. In 1984 Dr Guy moved to become first Director of ClinicalDevelopment and then Assistant Medical Director of Napp Laboratories inCambridge. Between 1983 and 1985 Dr Guy founded and was a Partner inDatalink Biomedical, a company established to exploit a computerised digitallung function machine.

In 1985 Dr Guy founded the drug delivery company Ethical Holdings plc, ofwhich he was Chief Executive Officer and Chairman (from 1991), and led thecompany to its NASDAQ flotation in 1993 before leaving in 1997. Dr Guy received3i’s “Venturer of the Year” award in the Science and technology category.

Through Ethical he also pursued a policy of investment in otherpharmaceutical opportunities which led to the founding of Phytopharm plc,the plant medicines company listed on the UK stock exchange. Dr Guy was,until 1997, Chairman of Phytopharm the objective of which was to developplant-based medicines derived from traditional Chinese medicine.

Ethical also invested in the jet injector company Antares Pharma Inc (formerlyMedi-Ject Corporation) in 1994 and Dr Guy was a Director of the companyfrom November 1993 until January 2001.

In 1997 the Home Office granted Dr Guy licenses to cultivate, possess andsupply cannabis for research purposes and in 1998 GW Pharmaceuticals Plcwas established through which to operate these licenses. The objective of GWwas, and remains, to develop a portfolio of non-smoked, prescriptioncannabis-based medicines and the Company has been carrying out a numberof Phase I, II and III clinical trials investigating the use of these medicines inmultiple sclerosis, neuropathic pain, spinal cord injury and cancer pain.

Simon HammettUK Life Sciences and Health Care Practice LeaderDeloitte

Simon Hammett is a Partner in the Consulting practice at Deloitte. He is asenior partner within our UK Strategy practice and also leads the EMEAGrowth and Innovation team. He focuses on Pharmaceuticals andManufacturing and has worked extensively with leading global pharmaceuticaland medical companies including: GlaxoSmithKline, Pfizer, British OxygenCompany and Roche.

Mr Hammett is very active in client service and focuses on competitivestrategy development, strategy implementation including enterprise-widetransformation, and CRM/sell-side solutions. He joined the firm from businessschool in 1993 with 6 years’ previous management experience. His experienceincluded research management, new product development, new ventures,technical sales and enterprise strategy.

Mr Andrew JackPharmaceutical CorrespondentFinancial Times

Andrew Jack is a journalist with the Financial Times, currently based inLondon. He joined the newspaper in 1990, and worked as a correspondent inLondon, Paris and Moscow. Since 2005, he has covered pharmaceuticals andhealthcare. He is author of the books Inside Putin’s Russia (Granta/OxfordUniversity Press, 2005) and The French Exception (Profile Books/EditionsOdile Jacob, 2001). He graduated from Cambridge University, studied atHarvard University and worked for New York City Government and as afreelance consultant and writer before joining the FT.

Dr Panos KanavosLecturer, International Healthcare PolicyLondon School of Economics

Panos Kanavos is Senior Lecturer in International Health Policy in the Departmentof Social Policy, Merck Fellow in Pharmaceutical Economics and Head of theMedical Technology Research Unit at LSE Health. He is also Visiting Professorat the University of Lausanne. He has acted as advisor to a number ofinternational governmental and non-governmental organisations, including theWorld Bank, the World Health Organisation and the Organisation for EconomicCo-operation and Development, the American Association for Retired Personsand Ministries of Health in over 21 transition and developing countries. He iscurrently participating in the European Pharmaceutical Forum as advisor tothe European Commission. His research interests comprise comparativehealth policy and health care reform; pharmaceutical economics and policy;quality in health care; and the socio-economic determinants of health.

Mr Nick LowcockManaging DirectorWarburg Pincus

Nicholas J. Lowcock leads the firm’s healthcare investing activities in Europe.Mr Lowcock was with the Boston Consulting Group before he joined WarburgPincus in 1994. He previously worked in the pharmaceutical industry in theUnited Kingdom. Mr Lowcock received a B.A. (first class) in experimentalpsychology from Oxford University and an M.B.A. with distinction from TheWharton School at the University of Pennsylvania. He is a member of theboard of trustees of Project Hope UK, a charity devoted to improvinghealthcare in developing nations. Mr Lowcock is a director of Archimedes,Eurand, Euromedic and ProStrakan.

Speakers


–– 9 ––

Dr Louise MakinChief Executive OfficerBTG plc

Dr Louise Makin is currently Chief Executive Officer of BTG plc, which developsnovel pharmaceuticals and other medical technologies. She was appointedChief Executive Officer in October 2004 and has led the turnaround andstrategic repositioning of the company. Previously, Dr Makin was President ofthe Biopharmaceuticals Division of Baxter Healthcare Europe, after havingjoined Baxter in 2000 as Vice President, Strategy & Business DevelopmentEurope. Prior to Baxter, she spent 13 years with ICI and English China Clay.

Dr Makin holds an MA in Natural Sciences, a PhD in Metallurgy from theUniversity of Cambridge, and an MBA. She is also a Non Executive Director onthe Board of Premier Foods plc, Chairman of the Advisory Board of LancasterUniversity Business School and a Trustee of the Engineering Development Trust.

Dr Lynn MarksSenior Vice President, Infectious Diseases MedicineDevelopment Centre, GlaxoSmithKline

Dr Marks received his medical degree from the University of South AlabamaCollege of Medicine and is Board Certified in Internal Medicine and Infectious Diseases.

He joined SmithKline Beecham in 1993 as Associate Director and laterDirector, Anti-infectives Clinical Research, Development, and Medical Affairs.He then moved to the Consumer Healthcare Division where he held thepositions of Worldwide Medical Director, Rx to OTC Switch and then, VicePresident and Director, Worldwide Medical, Regulatory, and Toxicology.

Later he returned to Pharma as, Vice President, Global Commercial Strategy,Infectious Diseases and subsequently became Senior Vice President,Infectious Diseases, Medicine Development Centre. Prior to joining industry, DrMarks was with the University of South Alabama College of Medicine, wherehe held the positions of Assistant Professor of Medicine in the Division ofInfectious Diseases and Adjunct Assistant Professor in the Department ofMicrobiology and Immunology as well as the Department of Pharmacology.His NIH supported research centred on the molecular genetics of Rickettsia.

Mr John Mayo CBEManaging General PartnerCeltic Pharma

John Mayo graduated in Economics from Loughborough University andqualified as a Chartered Accountant. As an investment banker in the eightiesand early nineties, John Mayo advised among others on the spin-off of ZenecaGroup plc by ICI plc; the privatisation of Irish Life ($750 million) and the IPO ofWellcome plc ($1.5 billion). In 1997, he initiated the merger between Zenecaand Astra, and in September 1997 John left to join The General ElectricCompany plc as Finance Director.

He has founded and grown several businesses including Beehive Capital LLP,and Salisbury Associates. During the last 10 years he has served as a non-executive director on the boards of the following public companies:Schlumberger, Alstom, Newcastle United, and Pentland. He has also served onthe following UK public bodies: The Takeover Panel; The Confederation ofBritish Industry’s Companies Committee; Her Majesty’s Treasury PublicSector Productivity Panel; and the FTSE Policy Committee. In 1999, John Mayowas made a Commander of the British Empire (CBE), in recognition of hisservices to British industry. John Mayo is a founder of Celtic Pharma, a globalprivate equity firm focused on the pharmaceutical industry. He is a UK citizenand is based in London.

Mr John D MacCarthyVice President, Client Thought LeadershipIMS Health®

Mr MacCarthy is Vice President, Client Thought Leadership at IMS Health andis responsible for spearheading the development of the company's thoughtleadership based approach to customer engagement globally. He worksextensively with clients in both the US and Europe.

His background includes over 20 years experience in the pharmaceuticalindustry gained in a career that began at Beecham Research Laboratories(now part of GSK) in 1977. He later joined Pharmacia UK in 1984 where hespent a number of years in roles in Sales, Marketing Management andCorporate Development. In 1995, John was appointed V.P. Strategy forPharmacia & Upjohn Europe, based in Paris. He was a member of the UKintegration teams following the mergers of Kabi Vitrum with Pharmacia and ofKabi Pharmacia with Farmitalia Carlo Erba, and a member of the globalintegration team during the Pharmacia and Upjohn merger.

Since joining IMS Health in 1998, Mr MacCarthy has also been responsible forcreating the sales force effectiveness suite of offerings in Europe and has beena major contributor to the development of the continuum of information,analytics and consulting services in the region.

He has supported client management teams in the USA and most majorEuropean markets to develop action plans to drive measurable improvementin the performance of key brands. In one case, in a project covering over 10countries, an improvement in brand performance of over $40m was achieved.

Mr MacCarthy holds a Masters Degree in Business Administration and aBachelors degree in Applied Chemistry.


–– 10 ––

Mr Reynold W (Pete) MooneyGlobal Leader, Life Sciences ConsultingDeloitte Consulting LLP

Mr Mooney leads Deloitte’s U.S. life sciences consulting practice. A strategyand operations practitioner with over twenty two years of consultingexperience, he has assisted senior executives from many cultures address thedifficult, complex business issues associated with value creation throughgrowth, asset effectiveness and cost containment.

A long time European resident who has recently moved to the US, most of MrMooney’s experience has been international. He has conducted majorconsulting engagements in North and South America, Europe and Asia forpharmaceuticals companies, biotechs, medical device manufacturers, andspecialty and commodity chemicals manufacturers. His clients includecompanies such as Roche, Novartis, Amgen, Applied Bio, Stryker, Bayer,Johnson & Johnson, Pfizer, Akzo Nobel, Sanofi-Aventis, GlaxoSmithKline, DSM,Broken Hill Proprietary and the Government of Argentina.

Mr Mooney has held a number of leadership roles within the firm. He hasserved as the Chief Executive Officer of Deloitte Consulting Nederland B.V., asthe firm’s Industry Practice Director, Europe Manufacturing and as a memberof the firm’s European Management Committee.

Beginning his professional career with USX Corporation prior to joining ToucheRoss & Co., Mr Mooney then worked for Braxton Associates, a global strategyconsulting firm, for eight years before rejoining the merged Deloitte & Touche.He has a B.A. in History and Economics from Washington & Jefferson Collegeand an M.B.A. from the Katz School, University of Pittsburgh.

Dr Simon MoroneyChief Executive OfficerMorphoSys AG

Dr Simon Moroney is one of MorphoSys’s co-founders. He studied chemistryin his native New Zealand, and was a Commonwealth Scholar to the Universityof Oxford, where he completed a D. Phil. in Chemistry in 1984. Prior to co-founding MorphoSys in 1992, Dr Moroney held positions at the University ofCambridge, UK, at the University of British Columbia, Canada, and in theChemistry Department of the ETH in Zurich, Switzerland. Subsequently hewas an Associate in the Harvard Medical School, Boston, U.S.A., and anemployee of ImmunoGen Inc, where he worked on the development ofantibody-based cancer drugs. In 2002, Dr Moroney was awarded theBundesverdienstkreuz am Bande (Cross of the Order of Merit of the FederalRepublic of Germany) for his services to the biotechnology industry.

Mr Rajiv NarangFounder and Chief Executive OfficerErehwon Innovation Consulting Pvt Ltd

Mr Narang’s passion and mission is to fuel the growth of innovative leadersand organisations. He has, over the last 17 years, developed a keen insight into‘what does it take for leaders and organisations to innovate and grow’. He hasaccomplished this through leading ‘Innovation for growth’ assignments with anumber of organisations across different sectors. Some of his key clientsinclude Novartis, Nokia, Development bank of Singapore, Bank of America,ESPN, International Flavours and Fragrances, Max New York Life, Unilever,Motorola, Bharti – Airtel and Marico Industries.

He has also directly engaged in researching ‘Innovative leaders andorganisations’ especially in Asia to develop fresh path-breaking ideas andinsights and has been invited to speak at a number of national andinternational conferences. Some of these are The Strategic Innovators’ Forumat Barcelona, Delivering Effective Innovation at London, Unlocking Innovation –Convergence 2005 and 2006, The CII Innovation Summit, HRD Asia Congressin Singapore, The Economist Annual CEO’s Conclave, AIMA annual convention,FMCGs Conclave and CII’s India Governing Council. As a result of hisexperience in not only in business but social innovation, he has also beeninvited to consult with and guide large national and state level change andinnovation projects.

He is the innovation consultant to the ‘Innovation for India’ foundation and alsoa member of the managing council.

Mr Gary NoonChief Executive OfficerAegate

Gary Noon has 25 years’ experience in the pharmaceutical industry, fulfiling anumber of roles including senior positions in general management, marketing,business development and sales in the US and Europe. He has worked formany of the world’s leading pharmaceutical companies such as Roche, BristolMyers Squibb, Glaxo Wellcome and Warner Lambert and was President of IMSHealth in the US. He has particular expertise in strategic marketing, supplychain management and product development and commercialisation. Beforejoining Aegate, Mr Noon was Senior Vice President and Head ofPharmaceuticals at Diversa Corporation.

Speakers


–– 11 ––

Dr Jean-Pierre PaccaudDirector of Business DevelopmentDrugs for Neglected Diseases Initiative (DNDi)

Dr Jean-Pierre Paccaud is Director of Business Development at the Drugs forNeglected Diseases initiative (DNDi). In this role, he identifies businessopportunities and expands DNDi’s network of partners and collaborators tofacilitate the organization’s drug development efforts.

DNDi is an independent, not-for-profit drug development initiative working toresearch and develop new and improved treatments for neglected diseases,such as leishmaniasis, human African trypanosomiasis, Chagas disease, andmalaria. Prior to joining DNDi, Dr Paccaud founded Athelas SA, an antibacterialdrug discovery company which recently merged with MerLionPharmaceuticals Pte Ltd of Singapore. Dr Paccaud also served as BusinessDevelopment Manager for OM Pharma; consulted for a number ofbiotechnology investment funds; and was tenured at the University of GenevaMedical School, where he established a medical research group. Dr Paccaudperformed his post-doctoral studies at the University of California at Berkeley,after earning his PhD in clinical immunology at the University of GenevaSchool of Medicine.

Ms Ann PopeDirector, Markets and Projects – GoodsOffice of Fair Trading (OFT)

Ann Pope is a Director at the Office of Fair Trading, working in the GoodsMarket Grouping, which is responsible for projects in pharmaceutical markets.She is an economist and has worked on a variety cases at the OFT. Herpharmaceuticals experience includes the removal of RPM on over-the-countermedicines, the Competition Act investigation into Genzyme, the market studyon the PPRS and the current market study into medicines distribution.

Mr Martyn PostleDirector and FounderCambridge Healthcare & Biotech Ltd

Martyn Postle is a senior Director who has worked in and for the pharmaceuticalindustry for over 26 years. He held various management positions over a ten-year period with Eli Lilly in areas such as New Product Planning, BusinessDevelopment and Marketing. He left Lilly to join Rorer Healthcare in the UK,where he was Strategic Planning Director and a member of their ExecutiveCommittee. He has been a Principal in both KPMG’s and Coopers & Lybrand’sconsulting divisions where he led their respective pharmaceutical marketing andstrategy consulting efforts. Prior to founding Cambridge Healthcare & Biotechhas was a Senior Vice President of Cambridge Pharma Consultancy, where heled their Business and Marketing Strategy Group. He also spent 3 years as aninvestment banker with Dresdner Kleinwort Benson, where he was responsiblefor healthcare M&A projects based out of the bank’s London, Frankfurt and NewYork offices. Martyn has advised over 70 different pharmaceutical, biotech andhealthcare companies in a diverse range of projects. He is also the Chair of thepharmaceutical sector group of the Taiwan Britain Business Council.

Dr Steven PowellChief Executive OfficerPlethora Solutions Limited

Steven Powell joined Plethora as Chief Executive Officer in 2004. Prior to this hewas a director of the Gilde Biotechnology and Nutrition Fund, a pan-Europeanventure capital fund focused on investments in early-stage companies. In additionto his private equity experience, Dr Powell has 20 years of experience in thepharmaceutical and life sciences sector, latterly as Chief Executive Officer of UKquoted biopharmaceutical company KS Biomedix plc until its acquisition byXenova Group plc. He has worked in the pharmaceutical and life sciencesindustries in research and development, commercial and general managementroles, initially for Beecham Pharmaceuticals (GSK) and subsequently withWhatman, Chiroscience, Celsis and Active Biotech. He has also helped to establishand finance a number of small life science businesses in a non-executive role.

Dr Andy RichardsEarly Stage Biotechnology Investor

Dr Andy Richards is a serial Biotechnology entrepreneur and business angel.He is currently a director of Vectura , Biowisdom, VASTox, Theradeas, CancerResearch Technology (commercial arm of CR-UK) Babraham BioscienceTechnology, Aitua and is Chairman of Altacor and Pharmakodex.

Dr Richards has a PhD in Chemistry and spent his early career with ICI (nowAstraZeneca) and with PA Technology. He was a founder of Chiroscience andan executive director through to the merger with Celltech in 1999. Since thattime he has been founding and investing in new biotechnology companiesincluding several of those listed above as well as Arakis, Geneservice,Cambridge Biotechnology Ltd, Amedis Pharmaceuticals, Sirus Pharmaceuticalsand Daniolabs all of which were recently sold. He is a director of theBioindustry Association (BIA) a founder member of the Cambridge Angels, afounder investor in LibraryHouse and an advisor to Toscana Life Sciences.

Mr Angus RussellChief Financial OfficerShire plc

Prior to joining Shire, Mr Russell worked for ICI, Zeneca and AstraZeneca for atotal of 19 years. His last position was Vice President – Corporate Finance atAstraZeneca PLC, where he was responsible for financial input into M&Aactivities, management of tax, legal, and finance structure, investor relation’sactivities and the management of various financial risks. Prior to this, he held anumber of positions within ZENECA Group PLC and ICI including GroupTreasurer, Group Investor Relations Manager, Strategic Planner, MarketingManager and management accounting roles in manufacturing and R & Doperations. Mr Russell is a chartered accountant, having qualified with Coopers& Lybrand, and is a member of the Association of Corporate Treasurers.


–– 12 ––

Mr Christian SiebertDG Enterprise and IndustryEuropean Commission

Christian Siebert is Head of Unit in the European Commission, Enterprise andIndustry Directorate-General, Unit “Competitiveness in the PharmaceuticalIndustry and Biotechnology”. The activity of the unit includes thePharmaceutical Forum, a follow-up to the “G10 Medicines” group’s policyrecommendations on access of patients to medicines and on improvedconditions for innovation in the European pharmaceuticals industry. The unitalso contributes to the development/implementation of the EuropeanCommissions’ policy document and action plan “Life Sciences andBiotechnology – a Strategy for Europe”.

He joined the European Commission in 1991 and held previous positions in theEnterprise/Industry Department, dealing with biotechnology, the foodindustry, co-operation with Central/Eastern Europe and with GATT/WTOmatters. He also has been Assistant to the Director-General for Industry.

Mr Siebert graduated (M.A.) in Political Science and Economics at theUniversity of Mainz (Germany), before completing post-graduate studies atthe College of Europe (Bruges, Belgium).

Mr Shinichi TamuraChief Executive OfficerSosei Group Corporation

Mr Tamura is co-founder of Sosei Company Limited and has been its ChiefExecutive Officer since 1990, and since October 2006 Chief Executive Officer ofSosei Group Corporation. From 1988 to 1991, Mr Tamura was the RepresentativeDirector (Chief Executive Officer) for Genentech Ltd and was in charge of theJapanese operations for Genentech Inc. From 1986, he had been advisor forGenentech, IDEC, Geron and Kissei, among others, for various periods of time.Prior to that, he has held various positions in Planning and Development atFujisawa (Astellas) from 1978 to 1986. Mr Tamura has an MS in Biochemistryfrom the University of Tokyo, in addition to studying Cultural Anthropology.

Mr Brian ThornleyChief Operations OfficerAegate

Brian Thornley joined Aegate in August 2007 as Chief Operations Officer,bringing with him many years experience in the pharmaceutical industry.Previously, Mr Thornley was Director of European Supply Chain for GSK wherehe was responsible for managing the supply chain from 25 factories across 44countries in Europe. At GSK, he was also responsible for supporting Europeansales of £4.2Bn.

Mr Thornley is an active member of the European Federation ofPharmaceutical Industry and Associations (EFPIA)’s Distribution and SupplyChain Committee.

Mr Robert WessmanPresident and Chief Executive OfficerActavis Group

Robert Wessman joined the board in April 2007. He has been the Presidentand Chief Executive Officer of Actavis since 2002, following the merger withDelta, where he had served as Chief Executive Officer since 1999. Under MrWessman’s leadership, Actavis has experienced phenomenal growth, frombeing a small domestic company in Iceland to becoming one of the largestcompanies in the generics industry. A business administration graduate andlecturer at the University of Iceland, he worked previously at Icelandictransportation company Samskip, advancing to the post of Chief ExecutiveOfficer in Germany. Mr Wessman is also a Board member of the IcelandChamber of Commerce.

Mr Dan ZabrowskiGlobal Head Pharma PartneringRoche

Dan Zabrowski is the Global Head of Pharma Partnering. In this role, DrZabrowski oversees Roche’s world class network of strategic alliances withbiotech companies and creates new alliances for the future. From 2002 to2007, Dr Zabrowski served as the Global Head of Pharma DevelopmentOperations and Vice President of Pharma Development, Nutley for Hoffmann-La Roche, Inc. This group is responsible for management of all global clinicaltrials for Roche.

Prior to this assignment, Dr Zabrowski was Global Head, Drug RegulatoryAffairs for Roche Pharma Division for 5 years. Dr Zabrowski joined Roche in1995 following the company’s acquisition of Syntex, Inc, where he held avariety of positions in Regulatory Affairs. Prior to that assignment, he ledRegulatory Affairs in North America for Fujisawa Pharmaceutical Company. DrZabrowski started his regulatory career at Searle. Before moving to theregulatory field, Dr Zabrowski conducted drug discovery research at Searle inserotonin receptor modulators.

Dr Zabrowski received a BA degree in Chemistry from Saint Louis Universityand a PhD in Organic Chemistry from Indiana University – Bloomington.

Speakers


–– 13 ––

Deloitte refers to one or more of Deloitte Touche Tohmatsu, a Swiss Verein, its member firms, and their respectivesubsidiaries and affiliates. Deloitte Touche Tohmatsu is an organisation of member firms around the world devoted toexcellence in providing professional services and advice, focused on client service through a global strategy executedlocally in nearly 140 countries.

With access to the deep intellectual capital of approximately 150,000 people worldwide, Deloitte delivers services in fourprofessional areas-audit, tax, consulting, and financial advisory services – and serves more than 80 percent of the world’slargest companies, including 85 percent of the Fortune Global 500® life sciences and health care companies, as well aslarge national enterprises, public institutions, locally important clients, and successful, fast-growing global companies.

www.deloitte.com

In association with


–– 14 ––

Almirall is an international pharmaceutical company that researches, develops, manufactures and commercialisesinnovative proprietary drugs and those under licence in order to improve people’s health and wellbeing. Almirall focuses itsresearch resources in the areas of asthma, COPD (Chronic Obstructive Pulmonary Disease), psoriasis, rheumatoid arthritisand multiple sclerosis.

Almirall is headquartered in Barcelona, Spain. The company employs approximately 3,000 people across the world, 30%of whom are based outside Spain. The company markets its drugs in more than 80 countries including the US and Japan,and has five affiliates in Europe (Germany, Belgium, France, Italy and Portugal) as well as one in Latin America (Mexico).2006 IMS figures show that Almirall is the third largest pharmaceutical company in Spain (behind Pfizer and Novartis) andis one of the top 40 largest pharmaceutical companies in Europe. The company was floated on the Spanish stockexchange on 20 June 2007.

www.almirall.es

Warburg Pincus has been a leading private equity investor since 1971. The firm currently has more than $20 billion ofassets under management. Since inception, Warburg Pincus has invested more than $26 billion in more than 575companies in 30 countries across a range of nine industry sectors. Healthcare is one of the firm’s core areas forinvestment globally, with members of our healthcare team focused on biotechnology, specialty pharmaceuticals, medicaldevices and healthcare services.

Our current European healthcare portfolio includes Archimedes Pharma, Eurand, Euromedic, ProStrakan and Tornier. Thefirm has invested over $4 billion in healthcare globally, of which over $1 billion has been invested in Europe. For moreinformation, visit:

www.warburgpincus.com

Sponsors


–– 15 ––

Aegate provides a unique patient safety service that supports pharmacists and pharmaceutical manufacturers in theauthentication of medicines. The service works in real time at the point of dispensing to ensure that patients do notinadvertently receive substandard products.

Once installed the service provides a direct, two-way communications network which links the pharmaceuticalmanufacturer and the pharmacist. This network acts as a protective mechanism by providing patient safety messagesdirect to pharmacists at the time when they are interacting with the product. This additional layer of security supportspharmacists by providing information on the specific pack being dispensed to ensure that counterfeit and stolenmedicines, out-of-date products or product recalls are inadvertently dispensed. In addition to providing information on thestatus of the pack of medicine being dispensed, the pharmacist can be provided with supplementary information aboutthe medicine. This information supports the pharmacist in ensuring that patients take their medication correctly gettingthe full benefit of their treatment.

Aegate's service authenticates medicines using an identification technique known as mass or unique serialisation, amethod by which items are identified by a unique individual number. Typically, these are applied by pharmaceuticalmanufacturers. The most commonly used technologies for unique serialisation are different types of barcodes, 1D or 2D, orRFID, Aegate can work with any type of code. The Aegate service is integrated into pharmacy software packages so thatpharmacists experience seamless dispensing.

Aegate's has been operational in Belgium since 2006 and launched in Greece this year. Aegate has also adapted theirtechnology to meet the needs of the developing world, by using a mobile phone and, a simple, cost effective 2D barcode theycan increase patient safety in a broad range of environments. Aegate has further plans for growth across Europe in 2008.

www.aegate.com

Operating in more than 100 countries, IMS Health is the world’s leading provider of market intelligence to thepharmaceutical and healthcare industries. With $2.0 billion in 2006 revenue and more than 50 years of industryexperience, IMS offers leading-edge business intelligence products and services that are integral to clients’ day-to-dayoperations, including portfolio optimisation capabilities; launch and brand management solutions; sales force effectivenessinnovations; managed care and over-the-counter offerings; and consulting and services solutions that improve ROI and thedelivery of quality healthcare worldwide. Additional information is available at:

www.imshealth.com

Roundtable hosts


–– 16 ––

Established in 1989, the BIA (BioIndustry Association) exists to encourageand promote a financially sound and thriving bioscience sector within the UKeconomy and concentrates its efforts on emerging enterprise and the relatedinterests of companies with whom such enterprise trades.

With over 300 members, the BIA supports a wide range of sectors, majoringon the human health benefits of the technology and represents the interests ofthese innovative companies to a broad section of stakeholders from patientgroups to politicians, advancing its members interests both within the UK andinternationally to create a healthy UK bioscience sector which benefits society.

www.bioindustry.org

BioPharm Insight™ provides mission critical information to life scienceprofessionals worldwide. Our focus is on providing the most up-to-date,forward looking insight to help our clients capitalize upon opportunities in theirbusiness. Through our global network of journalists and research analysts, weprovide analysis, research, and data that enables our clients to make faster,better decisions. Our on-line databases include information on: Clinical Trials,Investigational and Approved Drugs, Licensing Deals, Pharmaceutical Salesand Projections, Medical Devices, and Management Contacts.

www.biopharminsight.com

Bloomberg is the leading source of data, news and analytics for corporations,news organizations, financial professionals and individuals around the globe.The BLOOMBERG PROFESSIONAL® service and BLOOMBERG NEWS®

services provide real-time and historical pricing, indicative data, reporting,analytics, multimedia events and electronic communications to Bloombergclients in more than 125 countries, 24 hours a day.

www.bloomberg.com

European Biopharmaceutical Enterprises (EBE) is the European tradeassociation that represents biopharmaceutical companies of all sizesoperating in Europe. It was established in 2000 as a specialised group ofEFPIA and is headquartered in Brussels. Membership in EBE is open to allcompanies using biotechnology to discover, develop and bring new medicinalproducts to market. EBE’s focus on the biopharmaceutical sector providestargeted and results-oriented support for its members. It has developed awide range of activities and services for members, embracing policy advocacy,regulatory intelligence, strategic communications, business development,networking, education and training.

EBE has also developed specific programmes to address technical matters(e.g. biotech manufacturing standards and good practices) and cover growingniche markets (e.g orphan medicinal products).

www.ebe-biopharma.org

To serve the advancement of drug research, development and effective use byenhancing the efficiency of communication among pharmaceuticalresearchers and decision-makers, and by providing innovative solutions totheir information needs. Published by Informa Healthcare (publisher of Scrip,Biotechniques and the Taylor & Francis journals), the Expert Opinion serieswas developed in response to discussions with a wide range of decision-makers in pharma and biotech companies. The frequently stated need was forsystematic and authoritative analysis of all available information on patents,drug discovery, drugs in R&D and those on the market.

www.expertopin.com

Supporting partners


–– 17 ––

The leading online biopharmaceutical resource. InPharm provides industryexecutives with tailored information including:

Pharmafocus – A monthly newspaper-style publication for the pharmaceuticalindustry. Featuring exclusive news on the latest developments in marketingand R&D, and the changing NHS and regulatory environment.

InPharmjobs.com – Provides a comprehensive specialist online recruitmentservice for the pharmaceutical industry. One of the most widely used onlinerecruitment sites dedicated to the sector.

Pharmafile – The leading directory of specialist suppliers for people working inthe pharmaceutical and related industries. Published every six months,Pharmafile is the most up to date directory of the sector available anywhere.

www.inpharm.com

Pharmaceutical Executive Europe magazine is the leading strategy-based,business management publication for senior executives, corporate strategistsand sales and marketing leaders in the European pharmaceutical industry.

Tackling strategic business and marketing issues, Pharm Exec Europeprovides complete high-quality analysis, opinion and industry news on criticaltrends and developments; sales and marketing strategies; corporate policy,management and branding; research and development; legislation; finance;new technologies and much more.

Pharm Exec Europe is the indispensable read for senior pharmaceuticalexecutives who need to stay informed, innovative and ahead of the game.

www.pharmexeceurope.com

Pharmaprojects tracks every significant new drug under development fromlead through early preclinical study and clinical phases, to launched ordiscontinued status – and beyond. At the same time, we closely monitorcompany activity and therapeutic developments. The results of thisintelligence gathering, harnessed to Pharmaprojects' powerful functionality,means you can use our database to focus on what's critical to your business –reliable competitor intelligence.

In addition, you can use Pharmaprojects when benchmarking yourcompetitors’ R&D activity and performance, to assess potential businesspartners, identify in/out licensing opportunities and analyse industry trends,giving you the means to drive confident R&D strategy and decision-making.

www.pharmaprojects.com/research_development_analysis

Pharmawire publishes real-time news and data on the most price sensitiveissues in the global pharmaceutical market. Built for financial professionals,Pharmawire covers product approvals, litigation, licensing deals and M&A.Pharmawire is a part of The Mergermarket Group, a division of the FinancialTimes Group.

www.pharmawire.com

Whether you’re an industry leader or a rising star you need Scrip’s unique mixof succinct, straight-forward coverage of the issues that matter across thepharma industry. No other publication aids such complete industryknowledge. No other publication provides its coverage in such a digestiblestyle. And no other publication has provided such indispensable information toyour industry for over thirty years. That’s why pharmaceutical executives at alllevels, in all departments, rely on Scrip World Pharmaceutical News to helpthem achieve both company and individual success.

www.pjbpubs.com/scrip


Financial Times Global Conferences & EventsFinancial Times Conferences Global Conferences & Eventshas an international reputation for quality, agenda settingprogrammes and the ability to attract speakers of thehighest calibre. Our events offer senior executives theopportunity to attend proven forums and debates on keyissues, whilst providing a unique opportunity to networkwith high-level peers and potential clients.

Our annual conferences cover a wide range of keyindustry sectors, and our bespoke forums allow the clientto work with FT conferences in the development ofthemes and format. The FT Global Awards programmehas a reputation for excellence and the judging panels aredrawn from renowned experts in the fields of business,commerce and industry as well as senior editorial figuresfrom the Financial Times.

www.ftconferences.com

Financial Times ConferencesSponsorship Opportunities

For more information, please contact Toufique Khan:

Telephone: +44 (0)20 7873 3260Email: [email protected]

Delivering results for over 35 years

Organisers


Make your business a model of successFine tune to create the ultimate machine

Modern science refers to the human body’s intricate systems as the ultimate machine. The Life Sciences and Health Care practices of Deloitte Touche Tohmatsu (DTT) member firms have honed their experience working with the world’s largest life sciences companies to help you fine tune your intricate processes and operate as smoothly as nature’s example. Our member firms’ multi–functional teamshave the tools and comprehensive experience to help shape new strategies, improve operations, and achieve greater financial efficienciesas you strive to transform your organization into a model of success.

About Deloitte

Deloitte refers to one or more of Deloitte Touche Tohmatsu, a Swiss Verein, its member firms, and their respective subsidiaries and affiliates. Deloitte Touche Tohmatsu is an organization of member firmsaround the world devoted to excellence in providing professional services and advice, focused on client service through a global strategy executed locally in over 140 countries. With access to the deepintellectual capital of approximately 150,000 people worldwide, Deloitte delivers services in four professional areas—audit, tax, consulting, and financial advisory services—and serves more than 80 percentof the world’s largest companies, as well as large national enterprises, public institutions, locally important clients, and successful, fast-growing global companies. Services are not provided by the DeloitteTouche Tohmatsu Verein, and, for regulatory and other reasons, certain member firms do not provide services in all four professional areas.

As a Swiss Verein (association), neither Deloitte Touche Tohmatsu nor any of its member firms has any liability for each other’s acts or omissions. Each of the member firms is a separate and independentlegal entity operating under the names “Deloitte,” “Deloitte & Touche,” “Deloitte Touche Tohmatsu,” or other related names.

Copyright © 2007 Deloitte Development LLC. All rights reserved.

For more information, contact:

DTT – Life Sciences and Health CareRobert GoDeloitte Consulting LLP (US)+1 313 324 [email protected]

Europe, Middle East and AfricaStuart HendersonDeloitte & Touche LLP (United Kingdom)+44 1223 [email protected]

United KingdomSimon HammettDeloitte & Touche LLP (United Kingdom)+44 20 7303 [email protected]

www.deloitte.com/lifesciences


stand out

Why not take a free trial today and see how Scrip information differs from the rest

www.scripnews.com/trial

CS5766

JSN0013A

Find out what makes


–– 21 ––

Notes


–– 22 ––

Notes


–– 23 ––


–– 24 ––

Notes


–– 25 ––


–– 26 ––

Notes


www.ftpharmabiotech.com


FT GLOBAL PHARMACEUTICAL AND BIOTECHNOLOGY CONFERENCE 2007 Delegate... · FT GLOBAL PHARMACEUTICAL...

Documents

Transcript of FT GLOBAL PHARMACEUTICAL AND BIOTECHNOLOGY CONFERENCE 2007 Delegate... · FT GLOBAL PHARMACEUTICAL...